Scotland: Are Orphan Medicines Over Incentivized?
Executive Summary
Over the years, pharmaceutical companies in Europe have been given more incentives to develop orphan drugs, such as 10 years of market exclusivity. But with numbers of orphans on the rise, has the pendulum swung the other way?